JP2009530612A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530612A5
JP2009530612A5 JP2009500462A JP2009500462A JP2009530612A5 JP 2009530612 A5 JP2009530612 A5 JP 2009530612A5 JP 2009500462 A JP2009500462 A JP 2009500462A JP 2009500462 A JP2009500462 A JP 2009500462A JP 2009530612 A5 JP2009530612 A5 JP 2009530612A5
Authority
JP
Japan
Prior art keywords
subject
gelsolin
risk
level
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009500462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530612A (ja
JP5322917B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006451 external-priority patent/WO2007109056A2/en
Publication of JP2009530612A publication Critical patent/JP2009530612A/ja
Publication of JP2009530612A5 publication Critical patent/JP2009530612A5/ja
Application granted granted Critical
Publication of JP5322917B2 publication Critical patent/JP5322917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009500462A 2006-03-15 2007-03-15 炎症性疾患の診断および処置のためのゲルゾリンの使用 Active JP5322917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78250806P 2006-03-15 2006-03-15
US60/782,508 2006-03-15
PCT/US2007/006451 WO2007109056A2 (en) 2006-03-15 2007-03-15 Use of gelsolin to diagnose and treat inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270249A Division JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用

Publications (3)

Publication Number Publication Date
JP2009530612A JP2009530612A (ja) 2009-08-27
JP2009530612A5 true JP2009530612A5 (enExample) 2011-04-14
JP5322917B2 JP5322917B2 (ja) 2013-10-23

Family

ID=38522935

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009500462A Active JP5322917B2 (ja) 2006-03-15 2007-03-15 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2011270249A Withdrawn JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2014071355A Withdrawn JP2014122924A (ja) 2006-03-15 2014-03-31 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2015137491A Active JP6198777B2 (ja) 2006-03-15 2015-07-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2017098198A Active JP6568144B2 (ja) 2006-03-15 2017-05-17 炎症性疾患の診断および処置のためのゲルゾリンの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011270249A Withdrawn JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2014071355A Withdrawn JP2014122924A (ja) 2006-03-15 2014-03-31 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2015137491A Active JP6198777B2 (ja) 2006-03-15 2015-07-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2017098198A Active JP6568144B2 (ja) 2006-03-15 2017-05-17 炎症性疾患の診断および処置のためのゲルゾリンの使用

Country Status (13)

Country Link
US (3) US8198094B2 (enExample)
EP (2) EP2001496B1 (enExample)
JP (5) JP5322917B2 (enExample)
KR (2) KR20140091048A (enExample)
CN (2) CN107085113B (enExample)
AU (1) AU2007227613A1 (enExample)
CA (1) CA2680413C (enExample)
DK (2) DK3279663T3 (enExample)
ES (2) ES2895078T3 (enExample)
HU (2) HUE035884T2 (enExample)
PL (2) PL3279663T3 (enExample)
PT (2) PT3279663T (enExample)
WO (1) WO2007109056A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2848385T3 (es) * 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
CA2607686C (en) 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2002258B1 (en) 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
US7526337B2 (en) * 2006-06-06 2009-04-28 Cardiac Pacemakers, Inc. Method and device for lymphatic system monitoring
US20070282376A1 (en) 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
CN102119173B (zh) * 2007-08-15 2015-04-08 北京同为时代生物技术有限公司 凝溶胶蛋白结合剂组合物及其用途
JP5778425B2 (ja) * 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
EP2311823A1 (en) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
KR102176971B1 (ko) * 2012-07-05 2020-11-11 타이완 리포좀 캄파니 리미티드 관절염의 치료 방법
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
WO2015137738A1 (ko) * 2014-03-11 2015-09-17 한양대학교 산학협력단 혈액질환 진단
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
WO2016040987A1 (en) * 2014-09-15 2016-03-24 Abregen Pty Ltd Treating and/or preventing psoriasis
IT201700083044A1 (it) * 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
EP4204818A1 (en) * 2020-09-23 2023-07-05 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions
US20230357388A1 (en) * 2020-09-25 2023-11-09 The Francis Crick Institute Limited Immunotherapy
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
ATE171625T1 (de) 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
JPH05501503A (ja) 1990-05-04 1993-03-25 バイオジェン，インコーポレイテッド 多量体ゲルゾリン融合構築物
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
WO1994003601A2 (en) 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
WO1994008049A1 (en) 1992-10-01 1994-04-14 The General Hospital Corporation Functional assay for tumor suppressor genes
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
WO1995018799A1 (en) 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
CA2184385A1 (en) 1994-03-11 1995-09-14 Philip Davies Composition for the treatment of lung disease
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JPH10507765A (ja) 1994-10-27 1998-07-28 メルク フロスト カナダ インコーポレーテツド シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5774303A (en) 1995-03-24 1998-06-30 Stormedia, Inc. Sputter induced micro-texturing enhancement for magnetic head structures
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AU3817497A (en) 1996-07-30 1998-02-20 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
JP2001505219A (ja) 1996-12-04 2001-04-17 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷の治癒および線維症の治療
EP1003501B9 (en) * 1997-04-02 2005-06-08 The Brigham And Women's Hospital, Inc. Use of an agent for lowering the risk of cardiovascular disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001024827A2 (en) 1999-10-06 2001-04-12 Basf Aktiengesellschaft INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
JP2004532386A (ja) 2001-01-26 2004-10-21 オックスフォード グリコサイエンシズ（ユーケー）リミテッド 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
SG152907A1 (en) 2001-07-09 2009-06-29 Combinatorx Inc Combinations for the treatment of inflammatory disorders
EP1432728A4 (en) 2001-08-30 2007-10-24 Praecis Pharm Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
EP2266595A3 (en) 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1599226B1 (en) 2003-02-21 2012-09-19 Medvet Science Pty. Ltd. A method of diagnosis and treatment
EP1627076A4 (en) 2003-03-14 2008-07-02 Ppd Biomarker Discovery Scienc BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ES2848385T3 (es) 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20090053194A1 (en) 2003-12-22 2009-02-26 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
WO2005085859A1 (en) 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
CA2607686C (en) * 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
WO2007041245A2 (en) 2005-09-29 2007-04-12 Biogen Idec Ma Inc. Biomarkers for multiple sclerosis and methods of use thereof
EP2002258B1 (en) 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Similar Documents

Publication Publication Date Title
JP2009530612A5 (enExample)
Nofal et al. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
JP2020533381A5 (enExample)
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
Dufour et al. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease
CN110496124A (zh) 治疗脉管畸形的化合物
Li et al. Neuroprotective effect of electroacupuncture and upregulation of hypoxia-inducible factor-1α during acute ischaemic stroke in rats
Wang et al. Therapeutic efficacy of topical blockade of substance P in experimental allergic red eye
Arnaoutakis et al. Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest
CN106466318A (zh) 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
JPWO2019154900A5 (enExample)
WO2005030265A3 (en) Optical imaging of endometriosis
Li et al. Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage
Yang et al. Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss
James et al. Targeting the Signaling Domain of Aminopeptidase N Ameliorates Pulmonary Hypertension
Basharat Impact of Early Treatment on Healthcare Utilization and Risk of Osteoarthritis in Psoriasis Patients
Banek et al. RENAL SYMPATHETIC NERVES AND INFLAMMATION IN HYPERTENSION: ASSESSING RENAL INFLAMMATION RESPONSE TO RENAL DENERVATION BY URINARY CYTOKINE EXCRETION IN DEOXYCORTICOSTERONE-SALT RAT
Vodošek Hojs et al. MO147 ASSOCIATION OF CHA2DS2-VASC SCORE WITH CAROTID-FEMORAL PULSE WAVE VELOCITY IN CHRONIC KIDNEY DISEASE PATIENTS
Saita PS-C26-8: UNIQUE PROPERTIES OF DEPRESSOR, RENAL, AND ALDOSTERONE RESPONSES TO ALISKIREN THERAPY IN HYPERTENSIVE PATIENTS WITH NEPHROPATHY
Kawano et al. PS-C26-7: A SINGLE-CENTER, RETROSPECTIVE STUDY OF BLOOD PRESSURE EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Alfaro-Arnedo et al. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines 2021, 9, 912
Seront et al. Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort
Matlaga et al. 1899: Percutaneous Nephrostolithotomy: Impact of Access Point Number and Location on Complications
Jahnke et al. and Zebrafish Laser Injury Models
Matsuoka et al. PS-C26-6: HYPERTENSION DUE TO HYDRONEPHROSIS SECONDARY TO IGG4-RELATED DISEASE